[Oral contraceptives and thrombocytopenic thrombotic purpura].
López Izquierdo
A
A
Calvo-Villas
J M
JM
Ramírez-Sánchez
M
M
Sicilia Guillén
F
F
D000328:Adult; D001803:Blood Transfusion; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D003534:Cyproterone / Q000009:adverse effects*; D004176:Dipyridamole / Q000627:therapeutic use; D004958:Estradiol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D010949:Plasma; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced* / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use
D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D010975:Platelet Aggregation Inhibitors; D004958:Estradiol; D014750:Vincristine; D004176:Dipyridamole; D003534:Cyproterone; D011241:Prednisone